Who is the CEO of Amyris, Inc.?

Mr. Hermanus Kieftenbeld is a business executive who currently serves as the CEO of Amyris, Inc..

What is the Revenue Growth of Amyris, Inc.?

Revenue growth data for Amyris, Inc. is currently unavailable.

What is Amyris, Inc. operating Margin?

Amyris, Inc. operating margin is -219.63% which shows how much profit AMRS earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Amyris, Inc. operate?

Amyris, Inc. falls under the Basic Materials sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Amyris, Inc. revenue growth?

Revenue growth data for Amyris, Inc. is currently unavailable.

Amyris, Inc.

AMRS•NASDAQ

Basic MaterialsChemicals - Specialty

$0.05

$0.00(0.00%)

Amyris, Inc. (AMRS) Stock Overview

Explore Amyris, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for AMRSStats details for AMRS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for AMRSAnalyst Recommendations details for AMRS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.

CEO

Mr. Hermanus Kieftenbeld

Employees

1,598

Headquarters

5885 Hollis Street, EmeryVille, CA

Founded

2010